AP2369A - Carbonylamino pyrrolopyrazoles, potent kinase inhibitors. - Google Patents

Carbonylamino pyrrolopyrazoles, potent kinase inhibitors.

Info

Publication number
AP2369A
AP2369A AP2008004506A AP2008004506A AP2369A AP 2369 A AP2369 A AP 2369A AP 2008004506 A AP2008004506 A AP 2008004506A AP 2008004506 A AP2008004506 A AP 2008004506A AP 2369 A AP2369 A AP 2369A
Authority
AP
ARIPO
Prior art keywords
pyrrolopyrazoles
carbonylamino
kinase inhibitors
potent kinase
potent
Prior art date
Application number
AP2008004506A
Other languages
English (en)
Other versions
AP2008004506A0 (en
Inventor
Liming Dong
Chuangxing Guo
Yufeng Hong
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AP2008004506A0 publication Critical patent/AP2008004506A0/xx
Application granted granted Critical
Publication of AP2369A publication Critical patent/AP2369A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AP2008004506A 2005-12-21 2006-12-12 Carbonylamino pyrrolopyrazoles, potent kinase inhibitors. AP2369A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75334905P 2005-12-21 2005-12-21
US86493206P 2006-11-08 2006-11-08
PCT/IB2006/003646 WO2007072153A2 (en) 2005-12-21 2006-12-12 Carbonylamino pyrrolopyrazoles, potent kinase inhibitors

Publications (2)

Publication Number Publication Date
AP2008004506A0 AP2008004506A0 (en) 2008-06-30
AP2369A true AP2369A (en) 2012-02-29

Family

ID=38189022

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2008004506A AP2369A (en) 2005-12-21 2006-12-12 Carbonylamino pyrrolopyrazoles, potent kinase inhibitors.

Country Status (26)

Country Link
US (1) US7884117B2 (es)
EP (1) EP1979356B1 (es)
JP (1) JP4635089B2 (es)
KR (1) KR101029167B1 (es)
AP (1) AP2369A (es)
AU (1) AU2006327866B2 (es)
BR (1) BRPI0620354A2 (es)
CA (1) CA2634381C (es)
CR (1) CR10094A (es)
CU (1) CU23751B7 (es)
DK (1) DK1979356T3 (es)
EA (1) EA015513B1 (es)
EC (1) ECSP088558A (es)
ES (1) ES2435405T3 (es)
GE (1) GEP20104974B (es)
HR (1) HRP20130976T1 (es)
IL (1) IL191776A (es)
MA (1) MA30076B1 (es)
ME (1) ME00006B (es)
MY (1) MY151455A (es)
NO (1) NO20082482L (es)
NZ (1) NZ568692A (es)
PL (1) PL1979356T3 (es)
PT (1) PT1979356E (es)
RS (2) RS20080281A (es)
WO (1) WO2007072153A2 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL385265A1 (pl) * 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej
SG171914A1 (en) 2008-12-02 2011-07-28 Chiralgen Ltd Method for the synthesis of phosphorus atom modified nucleic acids
EP2451461A4 (en) 2009-07-06 2013-05-29 Ontorii Inc NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF
EP2937345B1 (en) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
DK2620428T3 (da) * 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
WO2012065935A1 (en) 2010-11-17 2012-05-24 F. Hoffmann-La Roche Ag Methods of treating tumors
US8771682B2 (en) 2011-04-26 2014-07-08 Technische Universtität Dresden Methods and compositions for reducing interleukin-4 or interleukin-13 signaling
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
WO2013074986A1 (en) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
KR20140135198A (ko) 2012-03-16 2014-11-25 에프. 호프만-라 로슈 아게 Pak1 억제제로 흑색종을 치료하는 방법
DK2872485T3 (da) 2012-07-13 2021-03-08 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
JP6246121B2 (ja) 2012-07-13 2017-12-13 株式会社新日本科学 キラル核酸アジュバント
CN112007045B (zh) 2012-07-13 2026-01-06 波涛生命科学有限公司 手性控制
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2015058140A1 (en) 2013-10-18 2015-04-23 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2015058126A1 (en) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
KR102423317B1 (ko) 2014-01-16 2022-07-22 웨이브 라이프 사이언시스 리미티드 키랄 디자인
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
JP6690543B2 (ja) 2014-10-31 2020-04-28 宇部興産株式会社 置換ジヒドロピロロピラゾール化合物
AU2015371251B2 (en) * 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
EP3307728A4 (en) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND CHINESE INHIBITORS
US10273252B2 (en) 2015-06-15 2019-04-30 Ube Industries, Ltd. Substituted dihydropyrrolopyrazole derivative
JP7028766B2 (ja) 2015-09-09 2022-03-02 ダナ-ファーバー キャンサー インスティテュート, インコーポレイテッド サイクリン依存性キナーゼの阻害剤
WO2017144546A1 (en) 2016-02-23 2017-08-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of nasopharyngeal carcinoma
JP7590185B2 (ja) 2018-06-25 2024-11-26 ダナ-ファーバー キャンサー インスティテュート, インコーポレイテッド Taireファミリーキナーゼインヒビターおよびそれらの使用
WO2020100944A1 (ja) 2018-11-14 2020-05-22 宇部興産株式会社 ジヒドロピロロピラゾール誘導体
WO2020140098A1 (en) * 2018-12-28 2020-07-02 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
EP3956446A1 (en) 2019-04-17 2022-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
CN114981298B (zh) 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
WO2021198511A1 (en) 2020-04-03 2021-10-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of sars-cov-2 infection
WO2022008597A1 (en) 2020-07-08 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of infectious diseases
WO2024261302A1 (en) 2023-06-22 2024-12-26 Institut National de la Santé et de la Recherche Médicale Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
WO2025078334A1 (en) 2023-10-09 2025-04-17 Institut National de la Santé et de la Recherche Médicale Combination of pak1 inhibitors and clk inhibitors for preventing resistance to chemotherapy in patients suffering from acute myeloid leukemia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012242A2 (en) * 2000-08-10 2002-02-14 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2004056827A2 (en) * 2002-12-19 2004-07-08 Pharmacia Italia Spa Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
WO2005030776A1 (en) * 2003-09-23 2005-04-07 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1527074A1 (en) 2002-07-25 2005-05-04 Pharmacia Italia S.p.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
GB0229526D0 (en) 2002-12-19 2003-01-22 Astrazeneca Ab Chemical compounds
KR100919343B1 (ko) 2005-01-10 2009-09-25 화이자 인코포레이티드 키네이스 억제제로서 피롤로피라졸

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012242A2 (en) * 2000-08-10 2002-02-14 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2004056827A2 (en) * 2002-12-19 2004-07-08 Pharmacia Italia Spa Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
WO2005030776A1 (en) * 2003-09-23 2005-04-07 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors

Also Published As

Publication number Publication date
ECSP088558A (es) 2008-07-30
NZ568692A (en) 2011-07-29
WO2007072153A2 (en) 2007-06-28
HK1128290A1 (en) 2009-10-23
JP2009520805A (ja) 2009-05-28
CA2634381A1 (en) 2007-06-28
EA015513B1 (ru) 2011-08-30
AU2006327866B2 (en) 2012-06-14
CU20080115A7 (es) 2010-08-30
MEP0808A (xx) 2010-02-10
JP4635089B2 (ja) 2011-02-16
WO2007072153A8 (en) 2008-08-14
IL191776A (en) 2013-03-24
IL191776A0 (en) 2008-12-29
US7884117B2 (en) 2011-02-08
CU23751B7 (es) 2012-01-31
CA2634381C (en) 2011-03-08
RS53029B (sr) 2014-04-30
ME00006B (me) 2010-02-10
MA30076B1 (fr) 2008-12-01
AU2006327866A1 (en) 2007-06-28
EA200801291A1 (ru) 2008-12-30
GEP20104974B (en) 2010-04-26
DK1979356T3 (da) 2013-11-18
AP2008004506A0 (en) 2008-06-30
US20090318440A1 (en) 2009-12-24
ES2435405T3 (es) 2013-12-19
HRP20130976T1 (hr) 2013-11-22
WO2007072153A3 (en) 2007-10-25
NO20082482L (no) 2008-07-02
EP1979356B1 (en) 2013-09-18
KR101029167B1 (ko) 2011-04-12
PL1979356T3 (pl) 2014-01-31
CR10094A (es) 2008-08-01
EP1979356A2 (en) 2008-10-15
MY151455A (en) 2014-05-30
PT1979356E (pt) 2013-11-21
KR20080080567A (ko) 2008-09-04
RS20080281A (sr) 2009-09-08
BRPI0620354A2 (pt) 2011-11-08

Similar Documents

Publication Publication Date Title
IL191776A0 (en) Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
ZA200705628B (en) Pyrrolopyrazoles, potent kinase inhibitors
EG25264A (en) Biphenyl-n-(4-pyridyl) methylsulfonamides.
AP2402A (en) Amine derivatives.
IL190078A0 (en) Kinase inhibitors
EG25271A (en) Fungicidal combinations.
GB2424882B (en) Selective kinase inhibitors
SI2270008T1 (sl) 8-heteroaril-3-alkil-1,3-dihidro-imidazo(4,5-c)kinolin-2-oni kot inhibitorji PI-3 kinaz
IL192033A0 (en) Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
AP2006003659A0 (en) Azabenzofuran substituted thioureas, inhibitors ofviral replication
AP2281A (en) Novel compounds.
ZA200805028B (en) Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor Xla inhibitors
PL1943243T3 (pl) Inhibitory kinazy
AP2337A (en) Motilide compounds.
AP2006003791A0 (en) 1-Heterocyclyl-1,5-dihydro-pyridoÄ3,2-BÜindol-2-ones
ZA200804667B (en) Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
NL1031384A1 (nl) Gesubstitueerde aryl-1,4-pyrazinederivaten.
GB0505823D0 (en) Boardmate, boardmate adjustable
GB0504761D0 (en) Alfatie, Coliawel, Omaatie
ITRM20050033U1 (it) Semicabina per fumatori.
ITTO20050072U1 (it) Armadio-espositore, particolarmente per tabaccherie
ZA200803287B (en) Kinase inhibitors
IL189985A0 (en) Kinase inhibitors
CY2449B1 (en) Multiple srengthened carton.
PL378279A1 (pl) Układ do osuszania gazów zwłaszcza dla komór klimatycznych